- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Cancer934
- Nervous System Diseases930
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Cancer934
- Nervous System Diseases930
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- KRAS positive
- PR positive
- EGFR positive
- PR negative
- EGFR negative
- ER negative
- BRAF positive
- PD-L1 negative
- ALK negative
- p16 positive
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- HLA-A positive
- IDH positive
- HR positive
- ALK positive
- NRAS positive
- CD19 positive
- TP53 positive
- MET positive
- ROS1 negative
- ROS1 positive
- HPV positive
- IDH negative
- MSI-H positive
- MYC positive
- PALB2 positive
- p16 negative
- BRAF negative
- HLA positive
- HPV negative
- ANA positive
- NF1 positive
- dMMR positive
- PIK3CA positive
- RAS positive
- anti-dsDNA positive
- CFTR positive
- MET negative
- HLA-A negative
- HRAS positive
- KRAS negative
- MGMT negative
- RB1 negative
- BCR-ABL1 positive
- BRCA positive
- FLT3 positive
- HBsAg positive
- HLA negative
- MMR positive
- NTRK positive
- RB1 positive
- RET positive
- anti-Sm positive
- ATM positive
- BCL2 positive
- CCND1 positive
- DMD positive
- FGFR2 positive
- KIT positive
- MGMT positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- ARID1A positive
- BCL6 positive
- CD30 positive
- CHEK2 positive
- FGFR3 positive
- FMR1 positive
- GRN positive
- HBV DNA negative
- HBV DNA positive
- HBsAg negative
- HR negative
- MSI-H negative
- MTAP positive
- NRAS negative
- PMS2 positive
- PTEN positive
- RAS negative
- RF positive
- STK11 positive
- TROP2 negative
- TROP2 positive
- ctDNA positive
- dMMR negative
- ABCA4 positive
- AChR positive
- APOL1 positive
- ARAF positive
- BRIP1 positive
- C5 positive
- CD123 positive
- CD5 positive
- CDK4 positive
- DLL3 positive
- DMPK positive
- EPCAM positive
- Ex19del positive
- FANCA positive
- FGFR positive
- KMT2A positive
- L858R positive
- MMR negative
- MSI positive
- MSS positive
- MuSK positive
- NF2 positive
- NPM1 positive
- NTRK negative
- PD-1 negative
- PD-1 positive
- PTPN11 positive
- Ph positive
- PiZZ positive
- RAD51 positive
- RAD54L positive
- RAF positive
- RET negative
- RUNX1 positive
- SMARCA4 positive
- SMN1 positive
- T790M positive
- TMB positive
- TP53 negative
- anti-AChR positive
- anti-Ro autoantibodies positive
- p53 positive
- AKT negative
- APC positive
- APP positive
- ASXL1 positive
- Anti-PLA2R positive
- BCR::ABL1 positive
- BRCA negative
- BRCA1 negative
- BRCA2 negative
- CD22 positive
- CD30 negative
- CD4 positive
- CDH1 positive
- CDK12 positive
- CLDN18.2 positive
- COL7A1 positive
- CRAF positive
- CRLF2 positive
- DGM7 positive
- DNMT3A positive
- EBV positive
- FAP positive
- FGFR2 negative
- FLT3 negative
- GPC3 positive
- HBB positive
- HBcAb negative
- HCV RNA positive
- HPV16 positive
- HRRm positive
- HbSS positive
- HbSβ0-thalassemia positive
- IL2RG positive
- Ki-67 positive
- LRRK2 positive
- MAP2K1 positive
- MDM2 positive
- MECP2 positive
- MSI negative
- MSS negative
- NF1 negative
- NTRK1 positive
- NUP98 positive
- NY-ESO-1 positive
- PAH positive
- PARP positive
- PIK3CA negative
- PRSS1 positive
- PSEN1 positive
- PSEN2 positive
- PTCH1 positive
- PTEN negative
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- RAF1 positive
- RHO positive
- SMN2 positive
- SOS1 positive
- SPINK5 positive
- T315I positive
- TSC1 positive
- TSC2 positive
- TTR positive
- UGT1A1 positive
- ZnT8 positive
- anti-HBc positive
- Gleason Score 10
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Alopecia from Prior Treatment
- Anti-Seizure Medications (up to 2 types)
- Antifibrotic Medications (Nintedanib, Pirfenidone)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
- Biologic Anti-Neoplastic Agent
- CD4+ > 350 cells/microliter for at least twelve months
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
6652 trials
Columbus, OH (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a drug to see if it's safe and effective to treat a lung disease called Idiopathic Pulmonary Fibrosis.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studied if digital therapies plus standard care can reduce symptoms of schizophrenia in teens & adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Graves Disease trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests batoclimab, a medication given as weekly injections under the skin, to see if it can help reduce eye bulging in patients with proptosis. The treatment starts with a higher dose for a few months, followed by a lower dose for a few more months. Batoclimab works by adjusting the immune system to decrease inflammation and swelling around the eyes.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a vaccine to protect older adults from serious E. coli infections. The vaccine trains the immune system to recognize and fight off nine types of harmful E. coli bacteria. In earlier studies, a similar vaccine caused fever and/or diarrhea in some participants and provided limited protection against illness.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug, lanifibranor, to see if it can treat adults with a fatty liver disease called NASH, and who also have liver fibrosis stage 2 or 3.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if a new drug, BHV-3000, is safe and effective in treating migraines in children and adolescents.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if lebrikizumab is effective and safe for adults with chronic sinus and nasal polyps who are already using nasal corticosteroids. The study will take around
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with a specific liver condition called non-cirrhotic NASH/MASH. The patients have significant liver damage but not cirrhosis. EFX aims to improve liver health by reducing swelling and scarring in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 43 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two treatments for women with moderate to severe acne. One treatment helps balance hormones to reduce skin oiliness, while the other kills bacteria and reduces inflammation. The goal is to see which treatment is more effective and potentially reduce the need for long-term antibiotic use.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved
Get notified when new Gastroparesis trials are postedWe'll send you an email whenever new trials are posted
SummaryThis trial seeks to evaluate if CIN-102 can reduce symptoms of diabetic gastroparesis in adults. Participants will compare effects of drug and placebo treatments over 12 weeks.
Columbus, OH (<10 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
1
2
3
…50